Providing a VOICE for Montana's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 2015
Meetings & Education
State & Federal Resources
National Professional Organizations
Off-Label Use Literature
Patient Advocacy Organizations
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Pembrolizumab for Advanced Cervical Cancer
On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
Read the full FDA press release here.